Close Menu

NEW YORK (GenomeWeb) – Asuragen said today that it is collaborating with Thermo Fisher Scientific to develop and commercialize capillary electrophoresis-based in vitro diagnostics.

Asuragen, based in Austin, Texas, will develop diagnostic kits for Thermo Fisher’s 3500 Dx Series Genetic Analyzer CS2 instrument, using its AmplideX PCR/CE technology, which enables the analysis of repetitive DNA sequences, and its AmplideX Reporter analytics and reporting software. The products will be built under design control and manufactured at Asuragen's cGMP facility.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.